$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
瑞格非尼治疗结直肠癌的用法用量
2025-10-19 11:44:20
Check Details
瑞格非尼为转移性结直肠癌患者带来了新的希望
2025-10-19 11:44:20
Check Details
瑞格非尼用于标准化疗失败的转移性结直肠癌患者
2025-10-19 11:44:20
Check Details
结直肠癌治疗药物瑞格非尼
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌(mCRC)
2025-10-19 11:44:20
Check Details
瑞戈非尼获批治疗转移性结直肠癌
2025-10-19 11:44:20
Check Details
瑞格非尼治疗转移性结直肠癌(mCRC)的疗效
2025-10-19 11:44:20
Check Details
瑞格非尼治疗晚期实体瘤I期剂量递增研究
2025-10-19 11:44:20
Check Details
瑞格非尼对伊马替尼和舒尼替尼治疗失败后胃肠道间质瘤的疗效:多中心II期试验
2025-10-19 11:44:20
Check Details
瑞格非尼治疗结直肠癌的疗效
2025-10-19 11:44:20
Check Details
瑞格非尼 vs Lonsurf结直肠癌 的真实世界治疗模式
2025-10-19 11:44:20
Check Details
瑞格非尼治疗结直肠癌效果优于安慰剂
2025-10-19 11:44:20
Check Details
1
2
...
7666
7667
7668
7669
7670
7671
7672
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Finerenone (Kerendia) for Diabetic CKD and HF with LVEF≥40%: Albuminuria, Dosing, Hyperkalemia
2
Baxdrostat (Baxfendy) for Hypertension: Aldosterone Synthase Inhibition, Dosing, and Discontinuation Rules
3
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
4
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
5
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
6
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
7
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
8
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
9
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
12
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission